Exploring Evrysdi: An oral, non-invasive treatment designed to produce SMN protein throughout the body

Tuesday, June 17, 2025
6:00 pm CT

Biaggis

5195 Utica Ridge Rd

Davenport, IA 52807

Genentech and its agents will collect your personal information in order to facilitate your registration. By submitting this registration I understand that my personal information, some of which may be considered sensitive information, such as information about health conditions, will be used and disclosed as described in Genentech’s Privacy Policy, and that I may be contacted using the information I have provided.

I will attend:* In Person Virtually

First Name*

Last Name*

Email Address*

Confirm Email Address*

Phone Number*

Address 1

Address 2

City

State

Zip Code*

What best describes you?*

Will any guests be participating in the event with you? How many?

For additional Genentech support services:

By checking this box and submitting this form, I am requesting Partnership and Access Liaison support, and disease education and other materials from and on behalf of Genentech and its affiliates. This may include information about products and services, including co-pay assistance or other patient support, opportunities to participate in surveys or provide feedback, or other topics. I understand that my personal information, which may include sensitive information, will be used and disclosed as described in Genentech’s Privacy Policy and that I may be contacted using the information I have provided. I understand providing this agreement is voluntary and plays no role in getting my medicine, and that I may opt out of receiving this information at any time by calling 877-436-3683. By submitting this form, I confirm that I am 18 years of age or older and that I agree to the Terms & Conditions.

By checking this box and submitting this form, I consent to receive autodialed calls and text messages, which may include marketing communications, from and on behalf of Genentech, including calls and/or text messages from a Partnership and Access Liaison, at the phone number(s) provided. I understand that consent is not a requirement of any purchase. Message frequency may vary. Message and data rates may apply. I may opt out at any time by texting STOP or calling 877-436-3683. I am also agreeing to the Privacy Policy and SMS Terms & Conditions.

Cancel

Location

Biaggis

5195 Utica Ridge Rd

Davenport, IA 52807

Speaker(s)

Shade Moody MD

Nemours Children's Hospital

Community Guest

Zack

Partnership and Access Liaison (PAL):

Julie Dibaise

Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:

are pregnant or plan to become pregnant, as Evrysdi may harm your unborn baby. Ask your healthcare provider for advice before taking this medicine
are a woman who can become pregnant:

Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy
Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping Evrysdi
Pregnancy Registry. There is a pregnancy registry for women who take Evrysdi during pregnancy. The purpose of this registry is to collect information about the health of the pregnant woman and her baby. If you are pregnant or become pregnant while receiving Evrysdi, tell your healthcare provider right away. Talk to your healthcare provider about registering with the Evrysdi Pregnancy Registry. Your healthcare provider can enroll you in this registry or you can enroll by calling 1-833-760-1098 or visiting www.evrysdipregnancyregistry.com

are an adult male. Evrysdi may affect a man’s ability to have children (fertility). Ask a healthcare provider for advice before taking this medicine
are breastfeeding or plan to breastfeed. It is not known if Evrysdi passes into breast milk and may harm your baby

Tell your healthcare provider about all the medicines you take
You should receive Evrysdi from the pharmacy as a liquid. If the medicine in the bottle is a powder, do not use it. Contact your pharmacist for a replacement
Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water
The most common side effects of Evrysdi include:

For later-onset SMA:

fever
diarrhea
rash

For infantile-onset SMA:

fever
diarrhea
rash
runny nose, sneezing, sore throat, and cough (upper respiratory infection)
lung infection (lower respiratory infection)
constipation
vomiting
cough

These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information.

Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.